This presentation provides an overview of the hepatitis C virus monitoring program implemented for state Medicaid to contain costs and to promote optimal member care. Key clinical and economic outcomes of the monitoring program are highlighted and formulary management strategies for novel hepatitis C virus agents identified.
The poster will address concerns about an increase in the use of behavioral medications in children and the need to manage prescribing practices to ensure appropriate use of the drugs.
This issue brief summarizes the key terms and conditions of the extension of a federal Section 1115 demonstration waiver for MassHealth, the Massachusetts Medicaid program. The waiver allows the Commonwealth to experiment with innovative strategies for delivering and financing health care for many of its Medicaid-eligible residents.
An industry overview and chartbook that provides a comprehensive look at the Massachusetts' hospital system.
In this commentary, the authors discuss, based on their experiences, concerns related to academic health centers partnering with correctional facilities, how existing partnerships have overcome those concerns, and the benefits of such relationships to both academic health centers and correctional facilities.
Results of a Massachusetts conducted focus groups with families about insurance quality measures.
Results of a Massachusetts conducted focus group with families about insurance quality measures.
This presentation discusses new payment models for asthma and provides an overview of the Massachusetts Children's High-risk Asthma Bundled Payment (CHABP) Demonstration Program. It also discusses opportunities and challenges of the new payment models.
This presentation outlines a successful hepatitis C medication monitoring program instituted by Clinical Pharmacy Services for MassHealth, the Massachusetts Medicaid program. The program used outreach and education strategies to communicate with prescribers about regimens that were the most effective in treating the virus and containing costs.
Presentation to Vermont's Green Mountain Care Board about a Price Variation Analysis undertaken in partnership with the University of Vermont College of Medicine and Wakely Consulting Group. The presentation outlined price variations across the state and suggested a process and methodology that the Board could use to set standard rates.
Katharine London joined a roster of health care leaders at a Brookings Institution MEDTalk on Medicaid innovation to discuss how alternative payment models can support innovative ways of providing care for children with asthma.
This analysis documents price variations across the state and suggests a process and methodology that the Vermont Green Mountain Care Board could use to set standard rates. The report determined that inpatient prices among Vermont's 14 hospitals and Dartmouth-Hitchcock Medical Center in New Hampshire vary from 71 to 130 percent of the state average.
Many primary care practices wish to become patient-centered medical homes, but the transformation process can be daunting. Here, three experts offer some professional advice.
This article discusses the economic impacts of Medicaid expansion under the Affordable Care Act and was based upon a presentation given by the authors in January 2014 at the Boston University School of Law symposium, "Improved Health at a Reduced Cost? Economic Perspectives on the Patient Protection & Affordable Care Act."
An email subject line can be a powerful first impression of an online survey.
This post offers ideas for creating subject lines that maximize email open rates and survey completion rates.
This article highlights a buprenorphine dose-based prior authorization policy developed by MassHealth, the Massachusetts Medicaid program, in consultation with UMass Medical School. The policy may be a model for other states that are concerned about diversion of buprenorphine among individuals with opioid dependence.
This presentation details the impact of state Medicaid programs placing lifetime limits on buprenorphine therapy for individuals with opioid dependence. The research reveals that setting limits does not save money or help the patient.
This presentation describes Medicaid & CHIP requirements to report performance indicators, describes the marketplace federal reporting requirements, describes and analyze initial results from the reporting requirements, and reviews the future of federal reporting for Medicaid & CHIP.
It is widely recognized that companies that embrace diversity and inclusion have a competitive advantage when recruiting employees and winning the loyalty of customers. This article explores how increasing the presence of disabled workers in the work force could have the same effect.
Presentation of study that found women with intellectual and developmental disabilities (IDD) comprise fewer than 1% of deliveries in the United States, but they and their infants are at significantly elevated risk of adverse outcomes.
This article examines the impact of a 2-year stepwise initiative to reduce utilization and therapy costs of long-acting opioid analgesics by addressing issues of high dose, daily dose, and preferred therapeutic alternatives. The study demonstrated that a state Medicaid program initiative can result in a significant decrease in opioid class utilization specifically for the targeted, more costly agents.